CAM 01
Alternative Names: C-AM-01Latest Information Update: 27 Jul 2022
Price :
$50 *
At a glance
- Originator Curatis
- Developer CapiThera
- Class Antimigraines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Migraine
Highest Development Phases
- Phase II Migraine
Most Recent Events
- 27 Jul 2022 CAM 01 is still in phase II trial for Migraine in Switzerland (unspecified route) (CapiThera Pipeline, July 2022)
- 02 Jan 2020 CAM 01 is available for licensing as of 02 Jan (CapiThera website,
- 02 Jan 2020 Phase-II clinical trials in Migraine in Switzerland (unspecified route) (CapiThera Pipeline,